公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2014 | Reply to E.R. Haspinger et al | CHIH-HSIN YANG ; Sequist L.V. | Journal of Clinical Oncology | 0 | 0 | |
2014 | Reply to F. de Marinis et al | CHIH-HSIN YANG ; Sequist L.V. | Journal of Clinical Oncology | 1 | 1 | |
2020 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG ; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. | The Lancet Respiratory Medicine | 39 | 37 | |
2013 | Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations | CHIH-HSIN YANG ; Hirsh V; Schuler M; Yamamoto N; O'Byrne K.J; Mok T.S.K; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist L.V. | Journal of Clinical Oncology | 293 | 242 |